In an online review posted Wednesday, FDA scientists did not reach a firm conclusion as to whether there was sufficient evidence of J & J boosters. Due to the shortcomings of the company’s data and the lack of information on protection against highly contagious delta variants of the coronavirus.
The review will take place prior to the Thursday and Friday meetings. The FDA Advisory Board recommends whether to support booster doses for both the J & J and Moderna vaccines... This is one step in the government’s vaccine review process. Next week, the FDA will make a final decision on the approval of these boosters, and the Centers for Disease Control and Prevention will discuss who actually should get them.
Adding complexity is whether it’s okay to use a different brand of booster than someone’s first shot. Preliminary results from a US government survey suggest that booster mixing and matching work at least as well-and perhaps much better for J & J recipients. According to results posted online on Wednesday, these people showed a stronger immune response when they took either Moderna or Pfizer shots as boosters than when they were vaccinated with another dose of J & J vaccine. .. Mix and match is also the subject of discussion by the FDA panel this week.
Health officials say all vaccines used in the United States continue to provide strong protection against serious illness or death from COVID-19.But with signs that protection against mild infections may be weakened, the government has already Clear booster dose of Pfizer vaccine For certain people starting 6 months after the last shot.
Aiming for unified recommendations, Moderna also asked the FDA to clear the booster dose in 6 months. However, J & J complicated the decision by proposing a second shot in the range of 2 to 6 months.
FDA reviewers suggest that a two-month booster program study “may be profitable,” but instead points out only a few people who got another shot in six months. I wrote that.
Overall, the J & J vaccine “still provides protection against severe COVID-19 illness and death,” the FDA reviewers concluded. However, its effectiveness data is “consistently less” than the protection seen in Pfizer and Moderna shots.
As part of that, J & J submitted data to the FDA from a real-world study that the vaccine is about 80% effective for hospitalization in the United States.
J & J’s single-dose vaccine was highly anticipated for its one-time formulation. However, its development was hampered by a series of problems, including rare but serious side effects, such as manufacturing problems and a neurological reaction called thrombosis and Guillain-Barré syndrome. In both cases, regulators have determined that the benefits of shots outweigh these risks.
Rival pharmaceutical companies Pfizer and Modana have provided most of the COVID-19 vaccine in the United States. Over 170 million Americans were fully vaccinated with two shots from these companies, while less than 15 million Americans received J & J shots.
The Associated Press’s Department of Health Sciences is supported by the Department of Science Education at the Howard Hughes Medical Institute. AP is solely responsible for all content.
Copyright © 2021 By AP communication. all rights reserved.
COVID Booster Shot: The FDA is working on whether to provide Johnson and additional doses of Johnson.Studies show that booster mixing is likely to be safe
Source link COVID Booster Shot: The FDA is working on whether to provide Johnson and additional doses of Johnson.Studies show that booster mixing is likely to be safe